2022 World Conference on Lung Cancer (ePosters)-EP07.03-006. Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data

EP07.03-006. Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data

Back to course

Pdf Summary

The management of malignant pleural mesothelioma (MPM) is difficult due to the high incidence of unresectable disease and low response rates to systemic therapy alone. Tumor Treating Fields (TTFields) therapy has been approved for use in MPM, but real-world data on its efficacy is limited. This study reviewed the cases of five patients with unresectable MPM who were treated with TTFields in combination with pemetrexed and platinum-based chemotherapy.<br /><br />The study aimed to evaluate the implementation, usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields therapy in real-world settings. The patients were enrolled in an FDA-required protocol and prescribed TTFields with a recommended usage of at least 18 hours per day applied to the thorax. They also received pemetrexed and platinum-based chemotherapy.<br /><br />The study found that none of the patients developed any Grade 4 adverse effects, and the median number of TTFields cycles was five. The median TTFields device usage in the first three months was 12.5 hours per day, which is 52% of the potential daily duration. Four out of five patients were alive at the time of analysis, and the 6-month and 1-year progression-free survival rates were 80% and 53%, respectively.<br /><br />These findings suggest that the combination of TTFields with pemetrexed and platinum-based chemotherapy is a feasible treatment strategy for appropriately selected patients with unresectable MPM. However, the study also highlighted the need for strategies to increase treatment usage rates and manage device-related skin adverse effects.<br /><br />Overall, this study provides valuable real-world data on the use of TTFields therapy in MPM treatment, confirming its potential as a treatment option for patients with this challenging disease.

Asset Subtitle

Rupesh Kotecha

Meta Tag

Speaker Rupesh Kotecha

Topic Mesothelioma, Thymoma, and Other Thoracic Malignancies - Thymoma

Keywords

malignant pleural mesothelioma

MPM

unresectable disease

systemic therapy

Tumor Treating Fields therapy

TTFields

pemetrexed

platinum-based chemotherapy

real-world data

clinical outcomes